These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19514326)

  • 1. [Hyperparathyroidism in patients on long-term hemodialysis].
    Rodosskaia NK; Orlova II; Brazhnikova VV
    Klin Med (Mosk); 2009; 87(4):68-70. PubMed ID: 19514326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Control of calcium and phosphate in hemodialysis patients].
    Eriguchi R; Takei S; Satou Y
    Clin Calcium; 2005 Sep; 15 Suppl 1():132-7; discussion 137. PubMed ID: 16272645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attainment of the Japanese Society for Dialysis Therapy guidelines for the management of secondary hyperparathyroidism in chronic hemodialysis patients in our clinic.
    Sato Y; Eriguchi R; Umakoshi J; Kato M
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S48-53. PubMed ID: 17976086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
    Kazama JJ
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors of Parathyroid Dysfunction in Elderly Patients with Chronic Kidney Disease Undergoing Hemodialysis.
    Li W; Zhang S
    Adv Clin Exp Med; 2015; 24(6):1007-12. PubMed ID: 26771973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Programmed approach to the treatment of secondary hyperparathyroidism in chronic renal disease].
    Samokhvalov NA; Maĭstrenko NA; Romashchenko PN
    Vestn Khir Im I I Grek; 2013; 172(2):43-6. PubMed ID: 24000678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sevelamer hydrochloride and vitamin D for controlling serum calcium, phosphorus and bone metabolism in patients undergoing hemodialysis].
    Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
    Clin Calcium; 2005 Sep; 15 Suppl 1():192-9. PubMed ID: 16279024
    [No Abstract]   [Full Text] [Related]  

  • 8. Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.).
    Torregrosa JV; Bover J; Cannata Andía J; Lorenzo V; de Francisco AL; Martínez I; Rodríguez Portillo M; Arenas L; González Parra E; Caravaca F; Martín-Malo A; Fernández Giráldez E; Torres A;
    Nefrologia; 2011; 31 Suppl 1():3-32. PubMed ID: 21468161
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification.
    Saab G; Whaley-Connell AT; Khanna R; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Dec; 1(2):107-12. PubMed ID: 19124399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid enlargement at dialysis initiation in patients with chronic kidney diseases.
    Nakai K; Fujii H; Kono K; Goto S; Miura S; Maeda A; Takeda K; Nishi S
    Ther Apher Dial; 2013 Feb; 17(1):24-9. PubMed ID: 23379489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium and phosphorus control in patients undergoing hemodialysis: from the view-points of activities of daily living.
    Osawa Y
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S54-61. PubMed ID: 17976087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achievement of the Japanese Society for Dialysis Therapy guideline targets for mineral metabolism measures: one Japanese university center result.
    Kimata N; Miwa N; Otsubo S; Iwasaki T; Yabuki Y; Miyabe K; Asamiya Y; Sato K; Sugi O; Ikebe N; Kiuchi K; Mineshima M; Akiba T
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S62-6. PubMed ID: 17976088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of subtotal parathyroidectomy in patients on haemodialysis].
    Vujić D; Majster Z; Lazić N; Radmirović A; Kekić Z
    Srp Arh Celok Lek; 1994; 122(1-2):34-7. PubMed ID: 17972801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Extraskeletal actions of parathyroid hormone in hemodialysis patients].
    Okuno S
    Clin Calcium; 2004 Jan; 14(1):27-31. PubMed ID: 15576950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Parathyroidectomy for advanced renal hyperparathyroidim in hemodialysis].
    Tominaga Y
    Clin Calcium; 2004 Sep; 14(9):93-6. PubMed ID: 15577119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients.
    Guideline Working Group, Japanese Society for Dialysis Therapy
    Ther Apher Dial; 2008 Dec; 12(6):514-25. PubMed ID: 19140852
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of severe metastatic calcification in hemodialysis patients.
    Yeh SM; Hwang SJ; Chen HC
    Hemodial Int; 2009 Apr; 13(2):163-7. PubMed ID: 19432688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient management of chronic kidney disease: proteinuria, anemia and bone disease as therapeutic targets.
    Lam A; Shah S; Paparello J
    Dis Mon; 2010 Apr; 56(4):215-32. PubMed ID: 20350654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hydroxyproline in the dialysate as a parameter of secondary hyperparathyroidism. Effects of phosphate reduction and alkalization].
    Schiessl JH; Schweigart U; Bottermann P; Kopp KF
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1310-3. PubMed ID: 25525
    [No Abstract]   [Full Text] [Related]  

  • 20. [PEIT is the part of strategy for severe hyperparathyroidism in patients requiring hemodialysis].
    Uemura K; Kakuta T
    Clin Calcium; 2004 Sep; 14(9):88-92. PubMed ID: 15577118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.